Download Oral Presentation (689.34 KB)

Symposium

ESPN •
17 October, 2025 •
•

Decoding complement in C3G and primary IC-MPGN Exploring evolving paths in care

Sally Johnson, Francesca Diomedi Camassei, Dieter Haffner

Available materials

Slides

Publication

ESPN •
16 October, 2025 •
•

Pegcetacoplan for paediatric patients with C3 glomerulopathy or primary immune-complex mediated membranoproliferative glomerulonephritis: 52-week results from Phase 3, VALIANT Study

Nicole CAJ Van de Kar, Gema Ariceta, Yael Borovitz, Bradley P Dixon, Larry A Greenbaum, Christoph Licht, Antonio Mastrangelo, Nabil Melhem, Nayoa Fujita, Dean Wallace, Marina Vivarelli, Zhongshen Wang, Dima Decker, Johan Szamosi, Lucía Quintana-Gallardo, Carla M Nester

Available materials

Oral Presentation

Publication

ASN •
8 November, 2025 •
•

Pegcetacoplan for 52 weeks results in sustained proteinuria reduction to remission (≤0.5 g/g) and normalization (≤0.2 g/g): Phase 3 VALIANT trial

Carla M Nester, Fadi Fakhouri, Daniel P Gale, Andrew S Bomback, Christoph Licht, Giuseppe Remuzzi, Nicole CAJ Van de Kar, Katie Gordon, Anwesha Mukherjee, Johan Szamosi, Lucía Quintana-Gallardo, Matthew C Pickering

Available materials

Oral Presentation

Publication

Pegcetacoplan halts disease progression and reduces proteinuria in paediatric patients with C3G and primary IC-MPGN: Phase 3 VALIANT study results

Decoding complement in C3G and primary IC-MPGN Exploring evolving paths in care

Pegcetacoplan for paediatric patients with C3 glomerulopathy or primary immune-complex mediated membranoproliferative glomerulonephritis: 52-week results from Phase 3, VALIANT Study

Pegcetacoplan for 52 weeks results in sustained proteinuria reduction to remission (≤0.5 g/g) and normalization (≤0.2 g/g): Phase 3 VALIANT trial

Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons

"Tiredness…That’s the main thing, this is why I work part time.": A thematic analysis of patient perspectives on care and unmet needs in C3G and primary IC-MPGN

Pegcetacoplan for 52 weeks maintained proteinuria reduction regardless of immunosuppressant use or nephrotic range proteinuria at baseline: VALIANT subgroup analysis

Pegcetacoplan halts disease progression and reduces proteinuria in paediatric patients with C3G and primary ​ IC-MPGN: Phase 3 VALIANT study results

Decoding complement in C3G and primary IC-MPGN Exploring evolving paths in care

Pegcetacoplan for paediatric patients with​ C3 glomerulopathy or primary immune-complex mediated membranoproliferative glomerulonephritis: 52-week results from Phase 3, VALIANT Study

Pegcetacoplan for 52 weeks results in sustained proteinuria reduction to remission (≤0.5 g/g) and normalization (≤0.2 g/g): Phase 3 VALIANT trial

Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons

"Tiredness…That’s the main thing, this is why I work part time.": A thematic analysis of patient perspectives on care and unmet needs in C3G and primary IC-MPGN

Pegcetacoplan for 52 weeks maintained proteinuria reduction regardless of immunosuppressant use or nephrotic range proteinuria at baseline: VALIANT subgroup analysis

Pegcetacoplan halts disease progression and reduces proteinuria in paediatric patients with C3G and primary IC-MPGN: Phase 3 VALIANT study results

Pegcetacoplan for paediatric patients with C3 glomerulopathy or primary immune-complex mediated membranoproliferative glomerulonephritis: 52-week results from Phase 3, VALIANT Study